Transactivation response (TAR) DNA-binding protein 43 (TDP-43), encoded by the *TARDBP* gene, is a highly conserved, ubiquitously expressed nuclear protein. It has conserved RNA recognition motifs (RRM1/RRM2) flanked on either side by N-terminal and glycine-rich C-terminal domains that mediate protein-protein interactions[@b1][@b2]. Recent studies show that TDP-43 is a nuclear ribonucleoprotein implicated in exon splicing, gene transcription, regulation of mRNA stability, mRNA biosynthesis, and formation of nuclear bodies[@b3][@b4][@b5][@b6][@b7][@b8][@b9][@b10][@b11]. Furthermore, TDP-43 is thought to be essential for early development, because homozygous disruption of the *TARDBP* gene causes early embryonic lethality[@b12][@b13].

TDP-43 is the major disease-associated protein involved in the pathogenesis of amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD) linked to TDP-43 pathology (FTLD-TDP)[@b14][@b15], and other neurodegenerative disorders[@b16][@b17][@b18][@b19][@b20]. Mutations of TDP-43 in familial and sporadic ALS and FTLD cases have been linked to the development of TDP-43 pathology[@b21][@b22][@b23][@b24]. These mutations are mostly located in the C-terminal glycine-rich region[@b25], suggesting that conformational change of this region is closely related to the pathology.

TDP-43 is predominantly localized in the nucleus, but under pathological conditions it is translocated to the cytosol[@b14][@b15][@b26][@b27][@b28][@b29][@b30]. Thus, loss of normal function of nuclear TDP-43 due to cytoplasmic mislocalization, and toxic gain of function due to TDP-43 aggregation are potential disease mechanisms[@b14][@b15].

Immunoblotting of the Sarkosyl-insoluble fractions from FTLD and ALS cases using phosphospecific antibodies clearly demonstrated that hyperphosphorylated full-length TDP-43 of 45 kDa, smearing substances, and fragments at 18--25 and 35kDa are the major species of TDP-43 [@b26][@b31][@b32]. We identified at least three C-terminal banding patterns that distinguish diseases with TDP-43 proteinopathy and reported that the banding pattern in different brain regions and spinal cord of individual patients is indistinguishable. Corresponding patterns of protease-resistant phosphorylated TDP-43 are also seen among the pathological phenotypes[@b26][@b27][@b32]. Recently, we showed that insoluble TDP-43 aggregates in brains of ALS and FTLD-TDP patients have prion-like properties[@b33].

TDP-43 phosphorylation, cleavage and cytoplasmic mislocalization are all associated with TDP-43 aggregation. However it remains to be clarified whether these modifications are the cause of the disease. Recent reports on post-translational modifications, including fragmentation, were based on studies of cellular or animal models overexpressing TDP-43 or its derivatives[@b34][@b35][@b36][@b37]. However, TDP-43 aggregate formation in these artificial models may be different from that in the brains of patients. Therefore, it is important and essential for elucidation of the pathogenesis to identify the pathological events in TDP-43 truly occurred in the brain of patients. In this study, we carried out detailed molecular analysis of pathological TDP-43 aggregates in ALS brains.

Results
=======

Immunoblot analysis revealed that abundant abnormal TDP-43 was recovered in the Sarkosyl-insoluble fractions of brains from both ALS cases as shown in [Fig. 1A](#f1){ref-type="fig"}. A phosphorylation-independent anti-TDP-43 detected normal TDP-43 of 43 kD in the fractions of both ALS and control brains, but also detected abnormal TDP-43 bands, including full-length phosphorylated TDP-43 of 45 kD, \~25 kD fragments and smears in ALS brains ([Fig. 1A](#f1){ref-type="fig"}). The pS409/410 antibody, which specifically recognizes the abnormal phosphorylation of Ser409 and 410 strongly reacted with these pathological TDP-43 bands and additional fragments of 18 \~ 24 kD ([Fig. 1A](#f1){ref-type="fig"}). No such bands were detected in the same fraction of control brain. Intensities of pS409/410 immunoreactive bands in both ALS cases were 5 \~ 10 times higher compared with those from the other cases previously analyzed in our lab (data not shown). Therefore, we thought these two cases are good for the protein chemical analysis of pathological TDP-43.

After SDS-PAGE, the gel portions corresponding to these bands were cut out as shown in [Fig. 1B](#f1){ref-type="fig"} and digested with trypsin and chymotrypsin. Digests were analyzed with nano-flow LC-MS/MS. As shown in [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}, we identified 229 peptides from brain of case 1 and 92 peptides from brain of case 2; this difference may reflect the differences in total amounts of pathological TDP-43 in these brains and the numbers of fractions. These peptides covered about 90% of the intact molecule ([Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}). Identified peptides (representative), modifications and cleavage sites are shown and summarized in [Figs 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}. Further cleavage site peptides are shown in [supplemental Fig. S1](#S1){ref-type="supplementary-material"}. Other proteins contaminating the Sarkosyl-insoluble fractions are listed in [supplemental Table S1](#S1){ref-type="supplementary-material"}.

Analysis of Case 1
------------------

We identified at least four intrinsically cleaved TDP-43 peptides in the pathological TDP-43, i.e., three N-terminal peptides (blue arrows, [Fig. 3A](#f3){ref-type="fig"}) and one C-terminal peptide (pink arrow). However, no caspase-cleaved peptides were detected in this study ([Table 3](#t3){ref-type="table"}). Ten serine residues were phosphorylated, as shown in [Fig. 3A](#f3){ref-type="fig"} and [Table 4](#t4){ref-type="table"}. These phosphorylation sites were the same sites as previously reported[@b27][@b38]. Furthermore, deaminations of Asn and Gln residues and oxidation of Met residues were identified. Almost all modification sites were found in the Gly-rich C-terminal half.

Analysis of Case 2
------------------

We identified six intrinsically cleaved TDP-43 peptides in this case, i.e., five N-terminal peptides (blue arrows, [Fig. 3B](#f3){ref-type="fig"}) and one C-terminal peptide (pink arrow). As shown in [Fig. 3B](#f3){ref-type="fig"} and [Table 4](#t4){ref-type="table"}, 15 serine residues were phosphorylated and 21 Asn/Gln residues were deamidated. Moreover, we found that the 79Lys residue was ubiquitinated and 82Lys was acetylated. However, 145Lys and 192Lys were not detected[@b39]. Phosphorylation sites were the same sites as previously reported[@b27][@b38]. Again, almost all of these modification sites were localized in the Gly-rich C-terminal half.

Common modifications in cases 1 and 2
-------------------------------------

All modifications are summarized in [Table 4](#t4){ref-type="table"}. As described above, almost all modifications were localized in the Gly-rich C-terminal half. Furthermore, common modifications focused on 180--330 residues region of these cases, suggesting that the 180--330 region of TDP-43 had the same structure in both case 1 and case 2.

Discussion
==========

Accumulation of filamentous inclusions composed of abnormally phosphorylated full-length TDP-43 (45 kDa) and its fragments (35 and 17--27 kDa) is a defining feature of TDP-43 proteinopathies[@b26]. It has been reported that overexpression of full-length TDP-43 with or without mutations in cultured cells and animals leads to fragmentation of the protein, generating 35-kDa (CTF-35) and 25-kDa (CTF-25) C-terminal fragments via caspase-mediated TDP-43 cleavage[@b30][@b34][@b40]. Furthermore, activation of calpain, a Ca^2+^-dependent cysteine protease, by upregulation of Ca^2+^-permeable AMPA receptors generates C-terminally cleaved TDP-43 fragments (\~35 kDa) and causes mislocalization of TDP-43 in motor neurons[@b36]. Those reports noted that the \~35 kDa fragments were localized in the cytoplasm and formed insoluble aggregates.

However, no such TDP-43 peptides cleaved by caspase or calpain reported were not detected in the pathological TDP-43 in the brains of patients in this study. On the other hand, uncleaved peptides by caspase or calpain were detected as the major molecules in the digests. Furthermore, several novel intrinsically cleaved TDP-43 peptides were identified in the pathological TDP-43, i.e., three and five N-terminal peptides (Cys164-Lys165, Tyr214-Gly215 and Asn279-Pro280 in case 1, and Arg55-Leu56, Val75-Asn76, Val108-Leu109, Val130-Leu131 and Asn279-Pro280 in case 2) ([Figs 3](#f3){ref-type="fig"}A,B and [4](#f4){ref-type="fig"} and [Table 3](#t3){ref-type="table"}) and two C-terminal peptide (Asn291-Ser292 in case 1 and Gly400-Phe401 in case 2) ([Figs 3](#f3){ref-type="fig"}A,B and [4](#f4){ref-type="fig"}), strongly suggested that these cleaved fragments under pathological conditions was different from that under TDP-43-overexpressing conditions.

Cellular expression of TDP-43 is tightly regulated at the transcriptional and post-translational levels. Under pathological conditions, however, formation of TDP-43 aggregates within the cell nucleus or cytoplasm results in reduced free nuclear TDP-43, and therefore the TDP-43 binding-receptor sensor detects a fall in protein levels and responds with increased TDP-43 production; the produced TDP-43 is then sequestered by TDP-43 aggregates[@b2]. Hence, TDP-43 production under pathological conditions does not necessarily represent overexpression. It is possible that TDP-43 aggregate formation under pathological conditions is different from that under TDP-43-overexpressing conditions.

It has been recently reported that C9ORF72 repeat expansions in mice cause TDP-43 pathology. In these mice, insoluble phosphorylated TDP-43 was predominantly present in monomeric form and high-molecular-weight or truncated pTDP-43 species were not detected[@b41]. Further, recombinant full-length human TDP-43 forms structurally stable, spherical oligomers that are neurotoxic *in vitro* and *in vivo*[@b42]. Indeed, cellular aggregate formation or accumulation of TDP-43 C-terminal fragments (CTFs) is not primarily responsible for development of the observed disease phenotype in mutant or wild-type TDP-43 mice[@b43][@b44][@b45]. These findings suggest that full-length TDP-43, not the cleavage fragments, participates at an early stage in TDP-43 pathology. Fragmentation may occur after the accumulation of TDP-43.

We identified some intrinsically cleaved TDP-43 peptides at the N-terminus and C-terminus of Sarkosyl-insoluble TDP-43 in this study. These cleavage sites were neither the caspase cleavage sites nor the calpain cleavage sites of TDP-43 as reported previously[@b46][@b47]. Several cleavage sites deduced from these N-terminal peptides exist in the region of residues 55--280 as shown in [Table 3](#t3){ref-type="table"} and [Fig. 4](#f4){ref-type="fig"}. Therefore, full-length TDP-43 may be gradually processed at N-terminal sites after the formation of insoluble aggregates as shown in [Fig. 4](#f4){ref-type="fig"}. Our findings that cleavage site is correlated with the distribution of molecular weight size are consistent with this idea. Further studies using antibodies for these cleavage sites will clarify the gradual processing mechanism.

In our previous studies, we identified phosphorylation sites by immunochemical methods[@b27] and also identified casein kinase-1 phosphorylation sites on recombinant TDP-43 [@b38]. Almost all Ser and Thr residues in C-terminal Gly-rich half were able to be phosphorylated *in vitro* experiment[@b38]. In the present work, however, a part of accumulated TDP-43 was phosphorylated, not all. Non-phosphorylated peptides were major products from aggregated TDP-43 digests from these ALS brains. We protein-chemically identified several novel phosphorylation sites by directly analyzing the accumulated TDP-43 from two ALS patients. Phosphorylation sites identified in case 1 and case 2 corresponded to the sites identified in casein kinase-1 phosphorylated TDP-43. Although 9 phosphorylation sites were common to both cases, more phosphorylation sites were identified in case 2, as shown in [Fig. 3A,B](#f3){ref-type="fig"}.

It has known that non-phosphorylated intact TDP-43 forms fibrous aggregate[@b42], suggesting abnormal phosphorylation is not first event in TDP-43 pathology. The level of phosphorylation may change according to the time when TDP-43 aggregates exist in cytoplasm. Phosphorylation-triggered degradation is a common strategy for elimination of regulatory proteins in many important signaling processes. Phosphorylation of TDP-43 may occur in elimination process. The impairment of this process due to TDP-43 aggregation will induce abnormal phosphorylation of TDP-43 aggregate. As the time has passed, the level of phosphorylation seems to become more. Therefore, the individual difference may occur in the level of phosphorylation.

Furthermore, it seems reasonable to speculate that heavily phosphorylated peptides may not be detected because of low recovery from the column and low ionization efficiency in mass analysis. S409/S410-phosphorylated TDP-43 was immunochemically included in almost all fractions as shown in [Fig. 1](#f1){ref-type="fig"}. However, we found small amount of peptide including S409 with phosphorylation in case 2, while we found no peptide S409/S410 with phosphorylation in case1. A peptide including S409/S410, which derived from chymotrypsin digestion, has at least 5 phosphorylation sites. We have already reported that TDP-43 C-terminal region including these phosphorylation sites was heavily phosphorylated[@b26][@b27][@b32]. Therefore, we might not detect C-terminal region peptide including S409/S410 residues. It is possible that there are some differences in phosphorylation states of accumulated TDP-43 and in the detection efficiency in the mass analysis between the cases.

Indeed, there were individual differences in other modifications, as shown in [Fig. 3A,B](#f3){ref-type="fig"}. However, we found that common modifications in case 1 and case 2 were focused in the 180--330 region ([Fig. 3A,B](#f3){ref-type="fig"}, and [Table 4](#t4){ref-type="table"}). This suggests that the 180--330 region of TDP-43 had the same structure in both case 1 and case 2.

Interestingly, inclusions within the brain of ALS and FTLD-TDP patients are readily labelled with antibodies that recognize the C-terminus of TDP-43, but not with N-terminal TDP-43 antibodies. In contrast, spinal cord inclusions are labelled with both N- and C-terminal TDP-43 antibodies, suggesting that they are composed of full-length TDP-43 [@b48]. This regional heterogeneity in terms of C-terminal fragment formation suggests that these fragments may not be necessary for TDP43-mediated neurodegeneration[@b49]. Furthermore, TDP-43 fragments generated during neurodegeneration were not C-terminal fragments, but rather were derived from a central portion of human TDP-43 [@b45]. These results indicate that a common structure region, residues 180--330 of TDP-43, is significant for neurodegeneration

It has already reported that a Gly-rich region (287--322), which contains multiple glycine repeats, may contribute significantly to fiber formation as well as aggregation propensity[@b50][@b51]. Recently, it has also been reported that the 274--414 GQN-rich region (C-terminal region) has prion-like properties[@b33][@b35], and that RRM2 domain of TDP-43 plays a key role in forming proteinaceous aggregates[@b52]. The common structure region, residues 180--330 of TDP-43, includes RRM2 and a part of the GQN-rich region. Therefore, this common structure region may be the core region of TDP-43 aggregates. The identification of N-terminal and C-terminal peptides in this study suggests that most of the cleavage sites exist in the N-terminal and C-terminal non-core regions. Proteolytic enzymes may readily access these regions and cleavage may occur gradually from distal regions. Our data provide important insight into the mechanism of TDP-43 accumulation, though further studies will be needed to clarify the molecular pathology of TDP-43 in detail.

Methods
=======

Fractionation of accumulated TDP-43 in ALS brain
------------------------------------------------

Sarkosyl-insoluble abnormal TDP-43 was prepared from brains of two ALS cases with abundant and widespread TDP-43 pathologies. Brain samples (0.5 g) from patients with ALS (case 1, 77-year-old male, disease duration 2.5 years and case 2, 57-year-old female, disease duration 2 years) and from vascular dementia (disease control, 88-year-old female) were homogenized in 10 ml of homogenization buffer (10 mM Tris--HCl, pH 7.5, containing 0.8 M NaCl, 1 mM EGTA, 1 mM dithiothreitol). Sarkosyl was added to the homogenates (final concentration: 2%), which were then incubated for 30 min at 37 °C and centrifuged at 20,000 g for 10 min at 25 °C. The supernatants were centrifuged at 100,000 g for 20 min at 25 °C. The pellets were further washed with sterile saline and centrifuged at 100,000 g for 20 min. The resulting pellets were used as Sarkosyl-insoluble fraction. This study was approved by the research ethics committee of Tokyo Metropolitan Institute of Medical Science (number: 15--5), and carried out in accordance with the approved guidelines. Informed consent about the brain donation was obtained from all subjects.

SDS-polyacrylamide gel electrophoresis (PAGE), immunoblotting and in-gel digestion
----------------------------------------------------------------------------------

The Sarkosyl-insoluble, SDS/urea-soluble fractions were separated on 4 \~ 20% polyacrylamide gradient gels by SDS-PAGE and immunochemically detected as described[@b26]. Briefly, for immunoblotting, mAb anti-TDP-43 (60019-2-Ig, 1:3000, ProteinTech Group), polyclonal anti-TDP (10782-1-AP, 1:3000, ProteinTech Group) and pS409/410 (rabbit polyclonal, 1:1000) were used. Bands of TDP-43 and its derivatives were excised and soaked in 50 mM Tris-HCl, pH 8.0, containing 50% acetonitrile for 30 min. The gel was dried in a Speed-Vac (Savant) and incubated in 50 mM Tris-HCl, pH 8.0 containing 125--250 ng of modified trypsin (Roche Diagnostics, Mannheim, Germany) or chymotrypsin (Roche Diagnostics, Mannheim, Germany) at 37 °C for 6--20 hours. The digests were extracted from the gel twice with 100 μl of 0.1% TFA containing 60% acetonitrile. These two extracts were combined, evaporated in a Speed-Vac, and stored at −80 °C until assayed.

Nano-flow liquid chromatography-ion trap mass spectrometry (LC-MS/MS)
---------------------------------------------------------------------

The sample was resuspended in 0.1% formic acid containing 2% acetonitrile and introduced into a nano-flow HPLC system, DiNa fitted with an automatic sampler (KYA Technology Corporation, Tokyo, Japan). A packed nano-capillary column NTCC-360/75-3*-*123 (0.075 mm I.D. ×125 mm L, particle diameter 3 μm, Nikkyo Technos Co., Ltd., Tokyo, Japan) was used at a flow rate of 300 nl / min with a 2--80% linear gradient of acetonitrile for 60 min. Eluted peptides were directly detected with an ion trap mass spectrometer, Velos Pro (Thermo Fisher Scientific Inc., Waltham, USA) at a spray voltage of 1.9 kV and a collision energy of 35%. The mass acquisition method consisted of one full MS survey scan followed by an MS/MS scan of the most abundant precursor ions from the survey scan. Dynamic exclusion for the MS/MS was set to 30 seconds. An MS scan range of 400--2000 m/z was employed in the positive ion mode, followed by data-dependent MS/MS using the CID or HCD operating mode on the top 10 ions in order of abundance. The data were analyzed with Proteome Discoverer (Thermo Fisher Scientific Inc., Waltham, USA), Mascot software (Matrix Science Inc., Boston, USA) and Scaffold software (Proteome Software, Inc., Oregon, USA). Swiss prot and GenBank databases were used.
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![SDS-polyacrylamide gel electrophoresis (PAGE) and immunoblotting of Sarkosyl-insoluble fraction from ALS case 1 brain and ALS case 2 brain.\
(**A**) A phosphorylation-independent anti-TDP-43 detected normal TDP-43 of 43 kD in the fractions of both ALS and control brains, but also detected abnormal TDP-43 bands, including full-length phosphorylated TDP-43 of 45 kD, \~25 kD fragments and smears in ALS brains. (**B**) TDP-43-positive bands were excised as indicated.](srep23281-f1){#f1}

![MS/MS identification of phosphorylated peptides and cleavage site peptides.\
Representative peptides were shown. (**A**) Chymotriptic peptide, 398-NGGFGSSM-405 in case 1. The 6th Ser residue was phosphorylated. (**B**)Triptic peptide, 56-LVEGILHAPDAGWGNLVYVVNYPK-79 in case 1. (**C**) Tryptic peptide, 215- GDVMDVFIPKPFR-227 in case 1. Trypsin can not cleave N-terminal Tyr214-Gly215 site. Therefore this site is intrinsically cleaved site. (**D**) Chymotryptic peptide, 56-LVEGILHAPDAGW-68 in case 2. Chymotrypsin can not cleave N-terminal Arg55-Leu56 site. Therefore this site is intrinsically cleaved site.](srep23281-f2){#f2}

![Identification of modification sites in TDP-43 from ALS case 1 (**A**) and case 2 (**B**) by LC-MS/MS analysis. Identified peptides from trypsin digestion (light green) and from chymotrypsin digestion (dark green) are shown. p indicates phosphorylation site. o indicates oxidation site. \* indicates deamidation site. Blue and pink arrows indicate N-terminal and C-terminal cleavage sites, respectively.](srep23281-f3){#f3}

![Schematic representation of N-terminal and C-terminal cleavage sites on TDP-43.\
Cleavage sites (amino acid numbering of TDP-43) in gel fractions and antibodies recognition sites were shown.](srep23281-f4){#f4}

###### List of identifid peptides derived from accumulated TDP-43 in ALS patient case 1.

  Query                 Start         End     Observed     Mr(expt)    Mr(calc)     Delta    Score    Expect                    Peptide
  --------------- ------------------ ----- -------------- ----------- ----------- --------- ------- ---------- -----------------------------------------
  **fraction1**    **chymotrypsin**                                                                            
  9373                   212          226     871.6568     1741.299    1741.8386   −0.5395    91     5.40E-09             F.SQYGDVMDVFIPKPF.R
  9389                   212          226     872.741      1743.4674   1741.8386   1.6288     41     0.00021              F.SQYGDVMDVFIPKPF.R
  9442                   212          226     880.2186     1758.4227   1757.8335   0.5892     60     2.70E-05            F.SQYGDVMoDVFIPKPF.R
  6387                   215          226     683.1282     1364.2418   1363.6846   0.5572     23      0.0077               Y.GDVMDVFIPKPF.R
  3616                   235          243     520.0455     1038.0765   1039.4223   −1.3458    24      0.025                 F.ADDQIAQSpL.C
  4502                   277          289     583.8335     1165.6524   1164.4949   1.1576     38     0.00028               F.GGNPGGFGNQGGF.G
  12543                  290          316     829.3413     2485.0021   2486.0452   −1.0431    45      0.0016       F.GNSRGGGAGLGN\*NQGSNMGGGMNFGAF.S
                     **trypsin**                                                                                                    
  7855                    84          95      641.5232     1281.0318   1280.5918    0.44      48     3.10E-05              R.KMDETDASSAVK.V
  8748                   103          114     671.5735     1341.1324   1340.7704    0.362     21      0.052                K.TSDLIVLGLPWK.T
  3193                   115          121     417.6076     833.2006    833.4131    −0.2124    26      0.0036                  K.TTEQDLK.E
  3198                   115          121     417.6429     833.2713    833.4131    −0.1417    23      0.0071                  K.TTEQDLK.E
  6245                   152          160     572.4623     1142.9101   1143.5448   −0.6347    20      0.014                  R.FTEYETQVK.V
  6249                   152          160     572.5684     1143.1223   1143.5448   −0.4225    24      0.0057                 R.FTEYETQVK.V
  10549                  215          227     513.2426     1536.7058   1535.7807   0.9252     26      0.025                 Y.GDVMDVFIPKPFR
  7515                   252          263     626.6138     1251.2131   1250.6619   0.5512     36      0.0004               K.GISVHISNAEPK.H
  7516                   252          263     626.6459     1251.2772   1251.6459   −0.3687    33      0.0037              K.GISVHISN\*AEPK.H
  10016                  276          291     742.3951     1482.7757   1482.6277    0.148     42     0.00011             R.FGGNPGGFGNQGGFGN.S
  12266                  276          293     863.7729     1725.5312   1725.7608   −0.2296    105    2.30E-10           R.FGGNPGGFGNQGGFGNSR.G
  12269                  276          293     864.0314     1726.0482   1725.7608   0.2874     103    2.30E-10           R.FGGNPGGFGNQGGFGNSR.G
  12274                  276          293     864.0852     1726.1559   1725.7608   0.3951     98     2.10E-09           R.FGGNPGGFGNQGGFGNSR.G
  12276                  276          293     864.1173     1726.2201   1725.7608   0.4592     97     2.30E-09           R.FGGNPGGFGNQGGFGNSR.G
  12278                  276          293     864.1233     1726.232    1725.7608   0.4712     101    3.40E-10           R.FGGNPGGFGNQGGFGNSR.G
  12279                  276          293     864.1337     1726.2528   1725.7608    0.492     111    8.90E-11           R.FGGNPGGFGNQGGFGNSR.G
  12280                  276          293     576.432      1726.274    1725.7608   0.5132     26      0.0082            R.FGGNPGGFGNQGGFGNSR.G
  12290                  276          293     576.6025     1726.7856   1725.7608   1.0248     36      0.0006            R.FGGNPGGFGNQGGFGNSR.G
  12268                  276          293     576.265      1725.7732   1726.7448   −0.9716    37      0.0007           R.FGGNPGGFGNQGGFGN\*SR.G
  12271                  276          293     864.0555     1726.0964   1726.7448   −0.6484    90     1.30E-08          R.FGGNPGGFGN\*QGGFGNSR.G
  **fraction2**    **chymotrypsin**                                                                            
  5089                   176          188     742.6311     1483.2476   1483.7518   −0.5042    43     0.00092              C.KLPN\*SKQSQDEPL.R
  5096                   176          188     743.321      1484.6275   1483.7518   0.8757     46     0.00041              C.KLPN\*SKQSQDEPL.R
  4168                   211          221     654.5313     1307.0479   1306.554    0.4939     39     0.00027                F.FSQYGDVMDVF.I
  6859                   211          226     945.4351     1888.8556   1888.907    −0.0514    48     3.70E-05            F.FSQYGDVMDVFIPKPF.R
  6861                   211          226     946.2177     1890.4207   1889.891    0.5298     30      0.0016            F.FSQ\*YGDVMDVFIPKPF.R
  6880                   211          226     953.7546     1905.4947   1904.9019   0.5928     52     4.10E-05            F.FSQYGDVMoDVFIPKPF.R
  3531                   212          221     580.9187     1159.8228   1159.4856   0.3373     35     5.70E-04               F.SQYGDVMDVF.I
  6412                   212          226     872.3367     1742.6589   1741.8386   0.8203     73     1.50E-07             F.SQYGDVMDVFIPKPF.R
  6461                   212          226     880.2487     1758.4828   1757.8335   0.6493     52     9.50E-05            F.SQYGDVMoDVFIPKPF.R
  4522                   215          226     682.6916     1363.3687   1363.6846   −0.3159    38     3.10E-04              Y.GDVMDVFIPKPF.R
  4524                   215          226     683.6007     1365.1869   1363.6846   1.5022     21     2.20E-02              Y.GDVMDVFIPKPF.R
  6869                   271          289     633.079      1896.2151   1897.8456   −1.6305    42     0.00049           L.ERSGRFGGNPGGFGN\*QGGF.G
  3544                   277          289     583.3915     1164.7685   1164.4949   0.2737     28      0.0025               F.GGNPGGFGNQGGF.G
  3546                   277          289     583.4573     1164.9001   1164.4949   0.4053     27      0.0051               F.GGNPGGFGNQGGF.G
  3548                   277          289     583.528      1165.0413   1164.4949   0.5465     30      0.0014               F.GGNPGGFGNQGGF.G
  7741                   290          313    1106.3008     2210.587    2210.9182   −0.3312    95     1.50E-08       F.GNSRGGGAGLGNNQGSN\*MGGGMNF.G
  7743                   290          313     737.9193     2210.7361   2210.9182   −0.1821    50     0.00044        F.GNSRGGGAGLGNNQGSN\*MGGGMNF.G
  7770                   290          313     743.0682     2226.1827   2226.9131   −0.7304    61     2.20E-05       F.GNSRGGGAGLGN\*NQGSNMoGGGMNF.G
  7772                   290          313     743.2908     2226.8505   2226.9131   −0.0626    38      0.0067        F.GNSRGGGAGLGN\*NQGSNMGGGMoNF.G
  7775                   290          313     743.557      2227.6492   2226.9131   0.7361     48     0.00017        F.GNSRGGGAGLGNNQGSN\*MGGGMoNF.G
  7791                   290          313    1121.8962     2241.7779   2241.924    −0.1461    65     7.30E-07       F.GNSRGGGAGLGNNQGSNMoGGGMoNF.G
  7792                   290          313     748.4241     2242.2504   2242.908    −0.6576    66     1.00E-05      F.GNSRGGGAGLGN\*NQGSNMoGGGMoNF.G
  7795                   290          313     748.7297     2243.1672   2243.892    −0.7248    36       0.01       F.GN\*SRGGGAGLGNNQ\*GSNMoGGGMoNF.G
  7796                   290          313     748.7909     2243.3508   2243.892    −0.5412    47     0.00068      F.GNSRGGGAGLGN\*NQGSN\*MoGGGMoNF.G
  7799                   290          313    1123.2252     2244.4359   2243.892    0.5439     69     3.10E-07     F.GNSRGGGAGLGN\*NQGSN\*MoGGGMoNF.G
  8563                   290          316     829.6099     2485.8078   2486.0452   −0.2374    58     8.60E-05      F.GN\*SRGGGAGLGNNQGSNMGGGMNFGAF.S
  8567                   290          316     830.2059     2487.5958   2487.0292   0.5666     67     1.20E-05     F.GNSRGGGAGLGN\*NQGSN\*MGGGMNFGAF.S
  8603                   290          316     834.7759     2501.3058   2503.0241   −1.7183    56     0.00012     F.GN\*SRGGGAGLGNNQGSNMGGGMoN\*FGAF.S
  8606                   290          316     835.1727     2502.4962   2503.0241   −0.5279    73     2.50E-06    F.GN\*SRGGGAGLGNNQGSNMoGGGMN\*FGAF.S
  8611                   290          316     835.5923     2503.755    2503.0241   0.7309     59     6.60E-05    F.GN\*SRGGGAGLGNNQGSNMGGGMoN\*FGAF.S
  8667                   290          316     840.1269     2517.3588   2518.035    −0.6762    61     4.90E-05     F.GNSRGGGAGLGNNQ\*GSNMoGGGMoNFGAF.S
  8671                   290          316     840.6654     2518.9744   2519.019    −0.0446    64     2.20E-05    F.GN\*SRGGGAGLGNNQGSNMoGGGMoN\*FGAF.S
  1915                   317          323     779.2965     778.2892    778.3353    −0.0462    37     0.00039                 F.SINPAMoM.A
  1916                   317          323     779.4086     778.4013    778.3353     0.066     37     0.00038                 F.SINPAMoM.A
  4592                   317          330     688.1877     1374.3609   1374.6635   −0.3026    28      0.0041              F.SINPAMMoAAAQAAL.Q
  4704                   317          330     696.6204     1391.2262   1391.6424   −0.4163    48     0.00028            F.SINPAMoMoAAAQ\*AAL.Q
  5282                   317          331     760.6963     1519.378    1518.717     0.661     62     1.30E-05            F.SINPAMoMoAAAQAALQ.S
  6767                   317          334     616.6206      1846.84    1846.8705   −0.0305    21      0.019             F.SINPAMMAAAQAALQSSW.G
  6768                   317          334     924.6777     1847.3409   1846.8705   0.4704     43     9.10E-05           F.SINPAMMAAAQAALQSSW.G
  6835                   317          334     941.1243     1880.234    1879.8444   0.3896     33      0.014           F.SINPAMoMoAAAQ\*AALQSSW.G
  3280                   324          334     552.4872     1102.9598   1102.5407   0.4191     68     7.20E-07               M.AAAQAALQSSW.G
  7465                   340          359    1037.6927     2073.3709   2072.893     0.478     38     0.00028           M.LASQQNQSGPSGNNQNQGNM.Q
  10098                  340          367    1015.7645     3044.2718   3044.3391   −0.0673    68     1.60E-05     M.LASQQNQSGPSGNNQNQGN\*MQREPNQAF.G
  10096                  340          367    1015.7145     3044.1216   3045.3231   −1.2014    60     8.90E-05    M.LASQQNQSGPSGNNQN\*Q\*GNMQREPNQAF.G
  10136                  340          367     1020.859     3059.5552   3060.334    −0.7788    75     9.60E-07     M.LASQQNQSGPSGNNQNQ\*GNMoQREPNQAF.G
  10145                  340          367    1021.6365     3061.8876   3061.318    0.5696     57     0.00017     M.LASQQNQSGPSGNNQ\*N\*QGNMoQREPNQAF.G
  10150                  340          367    1021.8416     3062.5028   3062.302    0.2008     45      0.0027    M.LASQQNQSGPSGN\*N\*Q\*NQGNMoQREPNQAF.G
  9721                   341          367     978.223      2931.6472   2931.255    0.3922     50     0.00076       L.ASQQNQSGPSGNNQNQGN\*MQREPNQAF.G
  9722                   341          367     978.352      2932.0343   2931.255    0.7793     48      0.0014       L.ASQQNQSGPSGNNQN\*QGNMQREPNQAF.G
  9763                   341          367     983.592      2947.7543   2947.2499   0.5044     34      0.012       L.ASQQNQSGPSGNNQNQGNMoQREPNQ\*AF.G
  9764                   341          367     983.6382     2947.8927   2947.2499   0.6428     40      0.0091      L.ASQQNQSGPSGNNQNQGNMoQREPNQ\*AF.G
  9765                   341          367     983.6984     2948.0733   2947.2499   0.8233     50     9.70E-05     L.ASQQNQSGPSGNNQNQGNMoQREPN\*QAF.G
  9772                   341          367     983.9515     2948.8328   2948.2339   0.5989     37      0.018      L.ASQQNQ\*SGPSGN\*NQNQGNMoQREPNQAF.G
  6163                   389          405     561.7853     1682.334    1680.5164   1.8176     20      0.034            A.SpNAGSpGSGFN\*GGFGSSM.D
  2063                   398          405     426.5261     851.0376    851.2521    −0.2145    13      0.063                 F.NGGFGSpSMo.D
  2064                   398          405     426.5549     851.0953    851.2521    −0.1568    13      0.057                 F.NGGFGSpSMo.D
                     **trypsin**                                                                                                    
  4541                   252          263     626.1067     1250.1988   1250.6619   −0.4631    47     3.70E-05              K.GISVHISNAEPK.H
  4554                   252          263     626.5655     1251.1164   1251.6459   −0.5295    30      0.0069              K.GISVHISN\*AEPK.H
  10298                  273          293     676.4501     2026.3284   2026.8994   −0.571     49     3.20E-05         R.SGRFGGN\*PGGFGNQGGFGNSR.G
  8412                   276          293     863.5454     1725.0763   1725.7608   −0.6845    68     4.20E-07           R.FGGNPGGFGNQGGFGNSR.G
  8413                   276          293     863.6377     1725.2608   1725.7608    −0.5      74     1.00E-07           R.FGGNPGGFGNQGGFGNSR.G
  8414                   276          293     863.6544     1725.2943   1725.7608   −0.4665    81     2.80E-08           R.FGGNPGGFGNQGGFGNSR.G
  8415                   276          293     863.7958     1725.577    1725.7608   −0.1838    96     4.00E-09           R.FGGNPGGFGNQGGFGNSR.G
  8421                   276          293     864.0331     1726.0516   1725.7608   0.2908     90     1.30E-08           R.FGGNPGGFGNQGGFGNSR.G
  8424                   276          293     864.0687     1726.1228   1725.7608   0.3619     82     2.10E-08           R.FGGNPGGFGNQGGFGNSR.G
  8425                   276          293     864.0773      1726.14    1725.7608   0.3792     102    8.60E-10           R.FGGNPGGFGNQGGFGNSR.G
  8426                   276          293     864.0829     1726.1512   1725.7608   0.3904     112    8.80E-11           R.FGGNPGGFGNQGGFGNSR.G
  8427                   276          293     864.0865     1726.1585   1725.7608   0.3977     83     1.60E-08           R.FGGNPGGFGNQGGFGNSR.G
  8428                   276          293     864.1036     1726.1926   1725.7608   0.4318     74     1.10E-07           R.FGGNPGGFGNQGGFGNSR.G
  8429                   276          293     864.1146     1726.2146   1725.7608   0.4537     103    5.60E-10           R.FGGNPGGFGNQGGFGNSR.G
  8416                   276          293     863.8204     1725.6263   1726.7448   −1.1185    87     2.10E-08          R.FGGNPGGFGN\*QGGFGNSR.G
  8417                   276          293     863.9819     1725.9493   1726.7448   −0.7955    88     2.50E-08          R.FGGN\*PGGFGNQGGFGNSR.G
  8419                   276          293     863.9979     1725.9813   1726.7448   −0.7635    90     1.30E-08          R.FGGNPGGFGN\*QGGFGNSR.G
  8420                   276          293     864.0292     1726.0438   1726.7448   −0.701     81     2.40E-08          R.FGGN\*PGGFGNQGGFGNSR.G
  8423                   276          293     864.066      1726.1175   1726.7448   −0.6273    69     1.70E-06          R.FGGN\*PGGFGNQGGFGNSR.G
  8430                   276          293     864.1177     1726.2209   1726.7448   −0.5239    90     1.20E-08          R.FGGN\*PGGFGNQGGFGNSR.G
  8434                   276          293     864.2111     1726.4077   1726.7448   −0.3371    96     3.30E-09          R.FGGNPGGFGN\*QGGFGNSR.G
  8435                   276          293     864.2555     1726.4964   1726.7448   −0.2484    95     4.30E-09          R.FGGNPGGFGN\*QGGFGNSR.G
  8436                   276          293     576.5455     1726.6148   1726.7448   −0.1301    31      0.012            R.FGGNPGGFGNQGGFGN\*SR.G
  8438                   276          293     864.4259     1726.8372   1726.7448   0.0924     82     1.00E-07          R.FGGN\*PGGFGNQGGFGNSR.G
  8439                   276          293     864.4338     1726.853    1726.7448   0.1082     82     1.00E-07          R.FGGNPGGFGN\*QGGFGNSR.G
  8440                   276          293     864.4481     1726.8817   1726.7448   0.1369     77     3.30E-07          R.FGGNPGGFGN\*QGGFGNSR.G
  8441                   276          293     864.4512     1726.8878   1726.7448    0.143     72     9.10E-07          R.FGGNPGGFGNQ\*GGFGNSR.G
  8443                   276          293     864.5175     1727.0205   1726.7448   0.2757     90     3.90E-09          R.FGGNPGGFGN\*QGGFGNSR.G
  8444                   276          293     576.6903     1727.0491   1726.7448   0.3043     40     0.00049           R.FGGNPGGFGNQGGFGN\*SR.G
  8445                   276          293     864.5552     1727.0959   1726.7448   0.3511     78     5.70E-08          R.FGGNPGGFGN\*QGGFGNSR.G
  8447                   276          293     864.6735     1727.3324   1726.7448   0.5875     78     1.50E-07          R.FGGN\*PGGFGNQGGFGNSR.G
  8448                   276          293     864.687      1727.3595   1726.7448   0.6146     81     2.60E-08          R.FGGN\*PGGFGNQGGFGNSR.G
  8446                   276          293     864.6155     1727.2164   1727.7288   −0.5124    79     1.50E-07         R.FGGN\*PGGFGNQ\*GGFGNSR.G
  8458                   276          293     865.0176     1728.0206   1727.7288   0.2918     53     1.20E-05         R.FGGN\*PGGFGNQGGFGN\*SR.G
  8463                   276          293     865.0424     1728.0703   1727.7288   0.3415     39     0.00023          R.FGGN\*PGGFGNQ\*GGFGNSR.G
  8470                   276          293     865.0927     1728.1707   1727.7288   0.4419     50     2.10E-05         R.FGGN\*PGGFGNQGGFGN\*SR.G
  8508                   276          293     865.5012     1728.9879   1728.7128    0.275     32      0.0016         R.FGGN\*PGGFGN\*Q\*GGFGNSR.G
  5555                   280          293     676.4501     1350.8856   1350.6065   0.2791     75     1.00E-07             N.PGGFGNQGGFGNSR.G
  **fraction3**    **chymotrypsin**                                                                            
  9282                   211          226     945.6774     1889.3402   1888.907    0.4332     32      0.001              F.FSQYGDVMDVFIPKPF.R
  8489                   212          226     872.2216     1742.4286   1741.8386    0.59      68     4.10E-07             F.SQYGDVMDVFIPKPF.R
  8572                   212          226     879.9073     1757.8001   1757.8335   −0.0333    33      0.0012             F.SQYGDVMoDVFIPKPF.R
  4043                   277          289     583.3818     1164.7491   1164.4949   0.2543     35     0.00048               F.GGNPGGFGNQGGF.G
  4044                   277          289     583.4044     1164.7942   1164.4949   0.2993     27      0.0032               F.GGNPGGFGNQGGF.G
  4048                   277          289     583.4793     1164.9441   1164.4949   0.4492     37     0.00059               F.GGNPGGFGNQGGF.G
  4057                   277          289     583.5714     1165.1283   1164.4949   0.6334     20      0.014                F.GGNPGGFGNQGGF.G
  10527                  290          313     743.5016     2227.4829   2225.9291   1.5539     32      0.0086         F.GNSRGGGAGLGNNQGSNMoGGGMNF.G
  10566                  290          313    1122.9318     2243.849    2243.892    −0.043     27      0.021       F.GNSRGGGAGLGN\*NQ\*GSNMoGGGMoNF.G
  11297                  290          316     840.3088     2517.9047   2518.035    −0.1303    38      0.0081      F.GNSRGGGAGLGN\*NQGSNMoGGGMoNFGAF.S
  11299                  290          316     840.5651     2518.6734   2518.035    0.6383     30      0.0058      F.GN\*SRGGGAGLGNNQGSNMoGGGMoNFGAF.S
  7796                   298          313     546.0648     1635.1726   1636.5535   −1.3808    24      0.082           A.GLGN\*NQ\*GSpN\*MGGGMNF.G
  5837                   317          330     688.5671     1375.1196   1374.6635   0.4561     25      0.0073              F.SINPAMMAAAQAAL.Q
  3589                   324          334     552.6029     1103.1912   1102.5407   0.6506     36      0.0017                M.AAAQAALQSSW.G
  1956                   398          405     426.5643     851.1141    852.2361    −1.122     23      0.038                F.N\*GGFGSpSMo.D
                     **trypsin**                                                                                                    
  6817                   103          114     671.6575     1341.3004   1340.7704    0.53      61     2.90E-06               K.TSDLIVLGLPWK
  4663                   152          160     572.6335     1143.2524   1143.5448   −0.2924    41     0.00021                 R.FTEYETQVK.V
  4677                   152          160     573.5289     1145.0432   1143.5448   1.4984     33     0.00079                 R.FTEYETQVK.V
  5751                   252          263     626.5578     1251.101    1251.6459   −0.5448    33      0.0017              K.GISVHISN\*AEPK.H
  11145                  276          293     864.0863     1726.158    1725.7608   0.3972     104    9.80E-10           R.FGGNPGGFGNQGGFGNSR.G
  11147                  276          293     576.6158     1726.8257   1725.7608   1.0649     43     0.00028            R.FGGNPGGFGNQGGFGNSR.G
  11138                  276          293     864.0644     1726.1142   1726.7448   −0.6306    99     3.00E-09          R.FGGN\*PGGFGNQGGFGNSR.G
  11140                  276          293     864.1228     1726.231    1726.7448   −0.5138    92     1.60E-08          R.FGGNPGGFGNQGGFGN\*SR.G
  11142                  276          293     864.1336     1726.2527   1726.7448   −0.4922    85     1.60E-08          R.FGGNPGGFGN\*QGGFGNSR.G
  11144                  276          293     864.2585     1726.5024   1726.7448   −0.2424    25      0.052            R.FGGN\*PGGFGNQGGFGNSR.G
  11157                  276          293     576.9172     1727.7297   1726.7448   0.9849     59     3.00E-05          R.FGGNPGGFGNQGGFGN\*SR.G
  **fraction4**    **chymotrypsin**                                                                            
  4202                   153          162     622.3894     1242.7642   1242.5802    0.184     40     0.00024                F.TEYETQVKVMo.S
  9557                   290          313     748.4747     2242.4024   2242.908    −0.5056    65     1.20E-05      F.GN\*SRGGGAGLGNNQGSNMoGGGMoNF.G
                     **trypsin**                                                                                                    
  15817                   56          79      875.6911     2624.0515   2623.3799   0.6716     30      0.0048         R.LVEGILHAPDAGWGNLVYVVNYPK.D
  15818                   56          79      875.9263     2624.757    2623.3799   1.3771     48     0.00018         R.LVEGILHAPDAGWGNLVYVVNYPK.D
  15822                   56          79      876.7198     2627.1377   2625.3479   1.7899     40      0.003        R.LVEGILHAPDAGWGN\*LVYVVN\*YPK.D
  5505                    84          95      641.2124     1280.4102   1280.5918   −0.1816    35      0.0015               R.KMDETDASSAVK.V
  5513                    84          95      641.6223     1281.2301   1280.5918   0.6383     64     1.20E-06              R.KMDETDASSAVK.V
  5516                    84          95      428.1922     1281.5549   1280.5918    0.963     30      0.0056               R.KMDETDASSAVK.V
  5728                    84          95      649.5043     1296.9941   1296.5867   0.4074     51     1.60E-05              R.KMoDETDASSAVK.V
  4136                    85          95      576.8164     1151.6183   1152.4969   −0.8786    32      0.0011                K.MDETDASSAVK.V
  4140                    85          95      576.885      1151.7555   1152.4969   −0.7414    20      0.013                 K.MDETDASSAVK.V
  4159                    85          95      577.0442     1152.0738   1152.4969   −0.423     22      0.008                 K.MDETDASSAVK.V
  4161                    85          95      577.0544     1152.0943   1152.4969   −0.4025    24      0.014                 K.MDETDASSAVK.V
  4173                    85          95      577.1104     1152.2063   1152.4969   −0.2906    50     2.10E-05               K.MDETDASSAVK.V
  4196                    85          95      577.2958     1152.577    1152.4969   0.0802     20      0.053                 K.MDETDASSAVK.V
  4204                    85          95      577.8925     1153.7704   1152.4969   1.2735     26      0.0035                K.MDETDASSAVK.V
  6390                   103          114     671.2714     1340.5282   1340.7704   −0.2422    54     1.80E-05              K.TSDLIVLGLPWK.T
  4096                   152          160     572.927      1143.8394   1143.5448   0.2946     39     0.00021                 R.FTEYETQVK.V
  4097                   152          160     572.9576     1143.9006   1143.5448   0.3558     28      0.0032                 R.FTEYETQVK.V
  4100                   152          160     573.1072     1144.1998   1143.5448    0.655     31      0.0023                 R.FTEYETQVK.V
  5209                   252          263     626.5698     1251.1251   1250.6619   0.4632     34     0.00061               K.GISVHISNAEPK.H
  10703                  276          293     864.0738     1726.1331   1725.7608   0.3723     108    2.10E-10           R.FGGNPGGFGNQGGFGNSR.G
  10689                  276          293     576.141      1725.4011   1726.7448   −1.3437    45     0.00089           R.FGGNPGGFG\*NQGGFGNSR.G
  10714                  276          293     864.5613     1727.1081   1727.7288   −0.6207    103    1.20E-09         R.FGGN\*PGGFGNQGGFGN\*SR.G
  **fraction5**    **chymotrypsin**                                                                            
  3922                   114          123     418.5765     1252.7075   1253.6139   −0.9064    38      0.0024                W.KTTEQDLKEY.F
  5597                   300          313     489.2062     1464.5969   1466.4479   −1.851     24      0.061           L.GN\*N\*QGS\*N\*MGGGMNF.G
  1088                   330          336     413.0149     824.0152    823.3534    0.6618     22      0.018                  A.LQSSWGMo.M
  8438                   386          405     658.5479     1972.6219   1974.5894   −1.9675    32      0.014           W.GSASNAGSGSpGFNGGFGSpSpM.D
                     **trypsin**                                                                                                    
  15330                   56          79      875.8154     2624.4245   2623.3799   1.0446     40     0.00088         R.LVEGILHAPDAGWGNLVYVVNYPK.D
  15331                   56          79      875.8346     2624.4819   2623.3799   1.1021     34      0.0077         R.LVEGILHAPDAGWGNLVYVVNYPK.D
  5230                    84          95      641.4845     1280.9544   1280.5918   0.3626     56     2.70E-05              R.KMDETDASSAVK.V
  5232                    84          95      641.5112     1281.0078   1280.5918    0.416     51     4.20E-05              R.KMDETDASSAVK.V
  3945                    85          95      576.9318     1151.8491   1152.4969   −0.6478    44     0.00018                K.MDETDASSAVK.V
  3952                    85          95      577.0027     1151.9908   1152.4969   −0.506     26      0.0054                K.MDETDASSAVK.V
  3958                    85          95      577.0422     1152.0699   1152.4969   −0.4269    50     1.90E-05               K.MDETDASSAVK.V
  3980                    85          95      577.1116     1152.2086   1152.4969   −0.2883    31      0.004                 K.MDETDASSAVK.V
  3983                    85          95      577.1158     1152.217    1152.4969   −0.2798    18      0.021                 K.MDETDASSAVK.V
  3990                    85          95      577.1333     1152.252    1152.4969   −0.2448    23      0.057                 K.MDETDASSAVK.V
  4006                    85          95      577.1882     1152.3619   1152.4969   −0.1349    25      0.0043                K.MDETDASSAVK.V
  4007                    85          95      577.1957     1152.3768   1152.4969    −0.12     30      0.0024                K.MDETDASSAVK.V
  4013                    85          95      577.2638     1152.513    1152.4969   0.0162     44     7.80E-05               K.MDETDASSAVK.V
  4018                    85          95      577.4311     1152.8476   1152.4969   0.3508     35      0.0031                K.MDETDASSAVK.V
  4021                    85          95      577.4545     1152.8944   1152.4969   0.3975     52     2.40E-05               K.MDETDASSAVK.V
  4030                    85          95      578.0698     1154.125    1152.4969   1.6281     33      0.0017                K.MDETDASSAVK.V
  4093                    85          95      585.0585     1168.1024   1168.4918   −0.3894    27      0.0031               K.MoDETDASSAVK.V
  4097                    85          95      585.7054     1169.3962   1168.4918   0.9044     24      0.0053               K.MoDETDASSAVK.V
  6018                   103          114     671.1033     1340.192    1340.7704   −0.5784    37     0.00067               K.TSDLIVLGLPWK.T
  3868                   152          160     573.0732     1144.1318   1143.5448    0.587     30      0.0028                 R.FTEYETQVK.V
  2331                   182          189     486.4414     970.8682    971.4672    −0.599     25      0.031                  K.QSQDEPLR.S
  2334                   182          189     486.5248      971.035    971.4672    −0.4322    25      0.017                  K.QSQDEPLR.S
  2345                   182          189     487.3027     972.5909    971.4672    1.1237     26      0.013                  K.QSQDEPLR.S
  10280                  276          293     864.1884     1726.3621   1725.7608   0.6013     106    3.40E-10           R.FGGNPGGFGNQGGFGNSR.G
  10284                  276          293     576.4902     1726.4489   1726.7448   −0.296     29      0.028            R.FGGNPGGFGNQ\*GGFGNSR.G
  10291                  276          293     864.5842     1727.1539   1726.7448   0.4091     90     2.20E-08          R.FGGNPGGFGNQGGFGN\*SR.G
  **fravtion6**    **chymotrypsin**                                                                            
  3105                   277          289     583.4806     1164.9467   1164.4949   0.4519     25      0.0045               F.GGNPGGFGNQGGF.G
  8141                   298          315     594.347      1780.0191   1778.6389   1.3802     32      0.015           A.GLGNNQGSpN\*MoGGGMNFGA.F
  7563                   300          316     565.4505     1693.3297   1693.5985   −0.2688    29      0.031          L.GN\*N\*QGSNMoGGGMoN\*FGAF.S
  5625                   317          330     486.4602     1456.3588   1455.6138   0.7449     18      0.041             F.SpIN\*PAMoMAAAQAAL.Q
                     **trypsin**                                                                                                    
  4254                   103          114     671.3554     1340.6963   1340.7704   −0.0741    36     0.00083               K.TSDLIVLGLPWK.T
  7335                   276          293     864.0093     1726.004    1725.7608   0.2432     65     2.40E-06           R.FGGNPGGFGNQGGFGNSR.G
  7340                   276          293     864.1556     1726.2966   1726.7448   −0.4482    87     4.90E-08          R.FGGNPGGFGN\*QGGFGNSR.G
  **fraction7**    **chymotrypsin**                                                                            
  4017                   277          289     583.4226     1164.8307   1164.4949   0.3358     32      0.001                F.GGNPGGFGNQGGF.G
  8195                   375          391     579.1056     1734.2949   1733.5372   0.7577     20      0.095           Y.SpGSN\*SGAAIGWGSpASpNA.G
  6844                   389          404     516.8932     1547.6579   1548.492    −0.834     23      0.065             A.SpNAGSGSGFNGGFGSSp.M
  9620                   389          409     673.531      2017.5712   2017.7361   −0.1649    20      0.078          A.SN\*AGSGSGFNGGFGSSpMDSKS.S
                     **trypsin**                                                                                                    
  7417                   103          114     671.6024     1341.1903   1340.7704   0.4199     39     0.00022               K.TSDLIVLGLPWK.T
  10947                  276          293     864.018      1726.0215   1725.7608   0.2606     108    3.50E-10           R.FGGNPGGFGNQGGFGNSR.G
  **fraction8**    **chymotrypsin**                                                                            
                                            not detected                                                                            
                     **trypsin**                                                                                                    
  4254                   103          114     671.3554     1340.6963   1340.7704   −0.0741    36     0.00083               K.TSDLIVLGLPWK.T
  7335                   276          293     864.0093     1726.004    1725.7608   0.2432     65     2.40E-06           R.FGGNPGGFGNQGGFGNSR.G
  7340                   276          293     864.1556     1726.2966   1726.7448   −0.4482    87     4.90E-08          R.FGGNPGGFGN\*QGGFGNSR.G

p indicates phosphorylation site; o indicates oxidation site; \* indicates deamidation site.

###### List of identifid peptides derived from accumulated TDP-43 in ALS patient case 2.

  Query                 Start         End   Observed    Mr(expt)    Mr(calc)     Delta    Score    Expect                       Peptide
  --------------- ------------------ ----- ----------- ----------- ----------- --------- ------- ---------- ------------------------------------------------
  **fraction1**    **chymotrypsin**                                                                         
  4855                   215          226   683.3186    1364.6226   1363.6846    0.938     17      0.066                    Y.GDVMDVFIPKPF.R
  20958                  290          313   738.3618    2212.0636   2210.9182   1.1455     28      0.0071            F.GNSRGGGAGLGNNQ\*GSNMGGGMNF.G
  21027                  300          321   742.2366    2223.6879   2222.8398   0.8481     27      0.048            L.GNNQGSpN\*MGGGMN\*FGAFSINPA.M
  21271                  316          336   771.2789    2310.815     2311.92    −1.1051    29      0.064            A.FSIN\*PAMoMoAAAQAALQSSpWGMo.M
  17965                  322          336   556.6434    1666.9085   1666.6078   0.3007     26      0.056               A.MMoAAAQ\*AALQ\*SSpWGMo.M
  10760                  389          398   489.2573      976.5     978.2968    −1.7968    23      0.057                  A.SpN\*AGSGSGFN\*.G
  10762                  389          398   489.3521    976.6897    978.2968    −1.6071    22      0.064                  A.SpN\*AGSGSGFN\*.G
                     **trypsin**                                                                                                    
  24329                  228          251   898.5277    2692.5613   2694.2652   −1.7039    38      0.0016           R.AFAFVTFADDQIAQS þ LCGEDLIIK.G
  12874                  252          263   627.0836    1252.1527   1250.6619   1.4908     46     7.90E-05                  K.GISVHISNAEPK.H
  19990                  276          293   863.7753    1725.5361   1725.7608   −0.2247    103    1.50E-09               R.FGGNPGGFGNQGGFGNSR.G
  20016                  276          293   864.1752    1726.3359   1725.7608   0.5751     121    5.20E-12               R.FGGNPGGFGNQGGFGNSR.G
  20030                  276          293   864.5692    1727.1239   1725.7608   1.3631     100    1.30E-09               R.FGGNPGGFGNQGGFGNSR.G
  **fraction2**    **chymotrypsin**                                                                         
  14560                   76          85    725.5255    1449.0365   1448.7194   0.3171     23      0.0065                   V.NYPKgDNKaRKM.D
  18417                  290          311   684.6705    2050.9898   2049.7041   1.2857     22      0.096         F.GN\*SpRGGGAGLGN\*N\*Q\*GSN\*MoGGGM.N
  15143                  382          397   502.4551    1504.3433   1504.5984   −0.2551    18      0.065                 A.AIGWGSASNAGSpGSGF.N
  17655                  389          405    615.114    1842.3202   1840.4491   1.8711     30      0.024              A.SpN\*AGSpGSpGFNGGFGSSpM.D
  12347                  398          408   421.6983    1262.0732   1261.3723   0.7008     23      0.078                   F.NGGFGSSpMoDSpK.S
  14828                  398          411   738.5961    1475.1776   1476.463    −1.2854    17      0.045                 F.NGGFGS.pSMDSKSpSG.W
                     **trypsin**                                                                                                    
  9063                    76          82    439.4402    876.8658    877.4294    −0.5635    21      0.065                      V.NYPKDNK.R
  12273                  152          160   572.6329    1143.2513   1143.5448   −0.2935    24      0.0066                    R.FTEYETQVK.V
  13442                  252          263   626.5903    1251.166    1250.6619   0.5041     60     2.20E-06                  K.GISVHISNAEPK.H
  18848                  276          293   864.1686    1726.3226   1726.7448   −0.4222    100    2.80E-09              R.FGGNPGGFGNQGGFGN\*SR.G
  18879                  276          293   865.5833    1729.1519   1727.7288   1.4231     92     2.30E-09             R.FGGNPGGFGN\*QGGFGN\*SR.G
  14839                  280          293   676.5123    1351.0101   1350.6065   0.4036     75     9.00E-08                 N.PGGFGNQGGFGNSR.G
  14842                  280          293   676.5812    1351.1478   1350.6065   0.5413     46     0.00033                  N.PGGFGNQGGFGNSR.G
  14844                  280          293   676.6381    1351.2617   1350.6065   0.6552     64     2.80E-06                 N.PGGFGNQGGFGNSR.G
  14837                  280          293   676.4991    1350.9837   1351.5905   −0.6068    33      0.0068                 N.PGGFGN\*QGGFGNSR.G
  **fraction3**    **chymotrypsin**                                                                         
  19885                  212          226   880.3099    1758.6053   1757.8335   0.7718     22      0.0093                 F.SQYGDVMoDVFIPKPF.R
  15096                  215          226   683.6068    1365.1989   1363.6846   1.5143     34     0.00061                   Y.GDVMDVFIPKPF.R
  4235                   230          234   584.3881    583.3808    583.3006    0.0802     26      0.0086                      F.AFVTF.A
  4246                   230          234   584.5333    583.5261    583.3006    0.2254     26      0.0084                      F.AFVTF.A
  18976                  290          307   831.7477    1661.4809   1662.7128   −1.2319    40     0.00047               F.GNSRGGGAGLGNNQGSNMo.G
  21767                  290          313   748.6056    2242.7949   2242.908    −0.1131    36      0.0087            F.GNSRGGGAGLGNNQGSNMoGGGMoNF.G
  20036                  298          315   594.1538    1779.4396   1780.607    −1.1674    26      0.065             A.GLGNN\*Q\*GSpN\*MoGGGMNFGA.F
  19286                  300          316   564.2299    1689.6679   1691.6304   −1.9625    23      0.057               L.GNNQGSNMoGGGMoN\*FGAF.S
  19330                  300          316   565.4157    1693.2251   1691.6304   1.5947     22      0.032               L.GNNQGSNMoGGGMoN\*FGAF.S
  21702                  300          321    741.259    2220.7553   2220.8718   −0.1165    20      0.068              L.GNNQGSpNMGGGMNFGAFSINPA.M
  21046                  341          359   654.4437    1960.3094   1960.7929   −0.4836    58     3.10E-05             L.ASQQNQSGPSGNNQNQ\*GNM.Q
  20839                  386          405   633.3611    1897.0616   1895.6071   1.4546     27      0.062              W.GSASpN\*AGSpGSGFNGGFGSSM.D
  21630                  389          411   727.5361    2179.5866   2177.7845   1.8021     32      0.027            A.SNAGSpGSGFN\*GGFGSSMoDSKSSG.W
                     **trypsin**                                                                                                    
  21995                  209          227   774.8737    2321.5992   2321.1191   0.4801     39      0.0013                R.EFFSQYGDVMDVFIPKPFR
  22343                  228          251   898.5321    2692.5745   2694.2652   −1.6907    45      0.0003            R.AFAFVTFADDQIAQSpLCGEDLIIK.G
  13384                  252          263    625.472    1248.9294   1250.6619   −1.7325    27      0.0032                   K.GISVHISNAEPK.H
  13416                  252          263   626.5458    1251.077    1250.6619   0.4151     28      0.0078                   K.GISVHISNAEPK.H
  13418                  252          263   626.6263    1251.238    1250.6619   0.5761     48     6.10E-05                  K.GISVHISNAEPK.H
  19580                  276          293   864.1287    1726.2429   1725.7608   0.4821     102    5.50E-10               R.FGGNPGGFGNQGGFGNSR.G
  19582                  276          293   864.1488    1726.283    1725.7608   0.5222     122    6.00E-12               R.FGGNPGGFGNQGGFGNSR.G
  19600                  276          293   865.1992    1728.3839   1728.7128   −0.329     28      0.036              R.FGGN\*PGGFGNQ\*GGFGN\*SR.G
  19637                  276          293   866.3511    1730.6877   1728.7128   1.9749     75     9.20E-08            R.FGGN\*PGGFGN\*QGGFGN\*SR.G
  **fraction4**    **chymotrypsin**                                                                         
  15701                  215          226   683.5077    1365.0008   1363.6846   1.3162     34      0.0018                   Y.GDVMDVFIPKPF.R
  15928                  317          330   689.0359    1376.0573   1375.6475   0.4098     27      0.0096                F.SIN\*PAMMoAAAQAAL.Q
  21325                  324          339   581.5296    1741.567    1739.6242   1.9428     19      0.085               M.AAAQAALQ\*SSpWGMoMoGMo.L
                     **trypsin**                                                                                                    
  14177                  252          263   627.0461    1252.0777   1251.6459   0.4318     35      0.0051                  K.GISVHISN\*AEPK.H
  23138                  273          293   676.4238    2026.2497   2025.9154   0.3342     47     0.00016              R.SGRFGGNPGGFGNQGGFGNSR.G
  20999                  276          293    863.697    1725.3794   1725.7608   −0.3815    105    8.20E-10               R.FGGNPGGFGNQGGFGNSR.G
  21025                  276          293   864.4716    1726.9286   1725.7608   1.1678     104    2.90E-10               R.FGGNPGGFGNQGGFGNSR.G
  **fraction5**    **chymotrypsin**                                                                         
  7104                   109          113   585.5835    584.5762    584.3322     0.244     26      0.0077                      V.LGLPW.K
  11793                  131          139   537.3479    1072.6812   1072.6314   0.0498     31      0.011                     V.LMVQVKKDL.K
  7071                   230          234   583.6779    582.6706    583.3006     −0.63     26      0.0074                      F.AFVTF.A
  7086                   230          234   584.4906    583.4833    583.3006    0.1827     26      0.0072                      F.AFVTF.A
  12944                  277          289   583.3265    1164.6384   1164.4949   0.1435     27      0.0028                  F.GGNPGGFGNQGGF.G
  15760                  298          311   696.9571    1391.8996   1391.437    0.4626     25      0.055               A.GLGNN\*Q\*GSpN\*MGGGM.N
  20561                  298          316   649.7761    1946.3065   1944.6543   1.6522     25      0.051           A.GLGN\*N\*Q\*GSpN\*MoGGGMoNFGAF.S
  22061                  314          337   863.6423    2587.905     2586.03     1.875     33      0.0056         F.GAFSpINPAMoMoAAAQ\*AALQSSWGMoMo.G
  12943                  375          385   583.3155    1164.6164   1165.3842   −0.7678    19      0.078                   Y.SpGSNSpGAAIGW.G
  22006                  375          400   845.8151    2534.4234   2532.8023   1.6211     27      0.061           Y.SGSNSpGAAIGWGSpASpNAGSpGSGFNGG.F
  11997                  389          400   546.7824    1091.5503   1092.3397   −0.7894    22      0.088                 A.SN\*AGSpGSGFN\*GG.F
                     **trypsin**                                                                                                    
  12956                  152          160   572.6786    1143.3427   1143.5448   −0.2021    36      0.0034                    R.FTEYETQVK.V
  21351                  209          227   775.3962    2323.1669   2322.1031   1.0638     17      0.069               R.EFFSQ\*YGDVMDVFIPKPFR.A
  14102                  252          263   626.5144    1251.0142   1250.6619   0.3524     39     0.00022                   K.GISVHISNAEPK.H
  18594                  276          293   863.6197    1725.2249   1725.7608   −0.5359    107    1.10E-10               R.FGGNPGGFGNQGGFGNSR.G
  **fraction6**    **chymotrypsin**                                                                         
  23141                  290          321   1054.8215   3161.4428   3162.1846   −0.7418    22     8.20E-02   F.GNSpRGGGAGLGN\*N\*Q\*GSNMoGGGMoNFGAFSpINPA.M
  22697                  297          322   897.8206    2690.4399   2689.0162   1.4237     23     5.50E-02         G.AGLGNNQGSpNMGGGMNFGAFSpINPAMo.M
  19240                  300          318   659.1209    1974.3407   1972.6969   1.6439     28     2.10E-02           L.GNNQ\*GSpN\*MoGGGMoNFGAFSI.N
  22742                  316          340   905.2916    2712.8529   2712.1167   0.7362     29     7.80E-02        A.FSINPAMMAAAQ\*AALQ\*SpSWGMoMGML.A
  13426                  317          330   481.3466    1441.0179   1439.6189   1.3989     21     4.30E-02               F.SpINPAMMAAAQ\*AAL.Q
  10747                  330          340   425.4213    1273.2422   1272.5189   0.7233     26     3.30E-02                A.LQ\*SSWGMMoGMoL.A
  16711                  388          404   567.5427    1699.6063   1700.4794   −0.8731    18     9.80E-02             S.ASpN\*AGSGSGFNGGFGSpSp.M
                     **trypsin**                                                                                                    
  8983                   182          189   486.6083    971.2021    971.4672    −0.2651    36     2.70E-03                    K.QSQDEPLR.S
  12216                  252          263   626.5559    1251.0973   1250.6619   0.4354     57     4.20E-06                  K.GISVHISNAEPK.H
  17819                  276          293   863.6684    1725.3222   1725.7608   −0.4386    123    7.00E-12               R.FGGNPGGFGNQGGFGNSR.G
  **fraction7**    **chymotrypsin**                                                                         
  14499                   56          68    689.5842    1377.1539   1376.7088   0.4451     56     9.80E-06                 R.LVEGILHAPDAGW.G
  18452                   56          71    831.8374    1661.6602   1660.8573   0.8029     40      0.0006                 R.LVEGILHAPDAGWGNL.V
  3963                   230          234    584.48     583.4727    583.3006    0.1721     26      0.0072                      F.AFVTF.A
  15174                  368          381   474.0898    1419.2475   1418.4024   0.8451     33      0.0091                F.GSpGNN\*SpYSGSNSGA.A
                     **trypsin**                                                                                                    
  21694                   56          79    876.0681    2625.1825   2624.3639   0.8186     61     7.10E-06           R.LVEGILHAPDAGWGN\*LVYVVNYPK.D
  10852                   84          95    641.5242    1281.0338   1280.5918    0.442     70     1.10E-06                  R.KMDETDASSAVK.V
  11727                  103          114   671.4896    1340.9647   1340.7704   0.1943     38     0.00025                   K.TSDLIVLGLPWK.T
  17298                  122          136   889.2975    1776.5804   1775.8804     0.7      69     1.90E-06                K.EYFSTFGEVLMVQVK.K
  8866                   152          160   573.5646    1145.1147   1143.5448   1.5699     26      0.0039                    R.FTEYETQVK.V
  10398                  252          263   626.6704    1251.3263   1250.6619   0.6644     37      0.0007                   K.GISVHISNAEPK.H

p indicates phosphorylation site; o indicates oxidation site; \* indicates deamidation site; a indicates acetylation site; g indicates ubiqutination site.

###### N-terminal sequences of abnormally accumulated TDP-43 fragments in human brain.

  Disease    Molecular weight      Sequence             Reference
  --------- ------------------ ----------------- -----------------------
  ALS             45kDa         56-LVEGILHA\--         this study
                  43kDa         56-LVEGILHA\--               
                30--35kDa         109-LGLPWK                 
                                  131-LMVQVKK                
                23--25 kDa      176-KLPNSKQ\--               
                                215-GDVMDVF\--               
                                280-PGGFGNQ\--               
                15--20 kDa       76-NYPKDNK\--               
                                215-GDVMDVF\--               
  FTLD-U        23--25 kDa      219-DVFIPKPF\--   Nonaka *et al.*[@b47]
                                247-DLIIKGI\--               
  FTLD-U          22 kDa        208-REFFSQY\--     Igaz *et al.*[@b44]

###### List of modifications in cases 1 and 2.

  Residue    Amino acid    Modification     Case1   Case2
  --------- ------------ ----------------- ------- -------
  70         Asparagine     deamidation       O       O
  76         Asparagine     deamidation       O        
  79           Lysine     ubiquitination              O
  82           Lysine       acetylation               O
  85         Methionine      oxidation        O        
  162        Methionine      oxidation        O        
  179        Asparagine     deamidation       O        
  213        Glutamine      deamidation       O       O
  218        Methionine      oxidation        O       O
  242          Serine     phosphorylation     O       O
  259        Asparagine     deamidation       O       O
  279        Asparagine     deamidation       O       O
  285        Asparagine     deamidation       O       O
  286        Glutamine      deamidation       O       O
  291        Asparagine     deamidation       O       O
  292          Serine     phosphorylation             O
  301        Asparagine     deamidation       O       O
  302        Asparagine     deamidation       O       O
  303        Glutamine      deamidation       O       O
  305          Serine     phosphorylation     O       O
  306        Asparagine     deamidation       O       O
  307        Methionine      oxidation        O       O
  311        Methionine      oxidation        O       O
  312        Asparagine     deamidation       O       O
  317          Serine     phosphorylation     O       O
  319        Asparagine     deamidation       O       O
  322        Methionine      oxidation        O       O
  323        Methionine      oxidation        O       O
  327        Glutamine      deamidation       O       O
  331        Glutamine      deamidation               O
  332          Serine     phosphorylation             O
  333          Serine     phosphorylation             O
  336        Methionine      oxidation        O       O
  337        Methionine      oxidation                O
  339        Methionine      oxidation                O
  346        Glutamine      deamidation       O        
  352        Asparagine     deamidation       O        
  353        Asparagine     deamidation       O        
  354        Glutamine      deamidation       O        
  355        Asparagine     deamidation       O        
  356        Glutamine      deamidation       O       O
  358        Asparagine     deamidation       O        
  359        Methionine      oxidation        O        
  366        Glutamine      deamidation       O        
  372        Asparagine     deamidation               O
  373          Serine     phosphorylation             O
  375          Serine     phosphorylation     O       O
  378        Asparagine     deamidation       O        
  379          Serine     phosphorylation             O
  387          Serine     phosphorylation     O       O
  389          Serine     phosphorylation     O       O
  390        Asparagine     deamidation               O
  393          Serine     phosphorylation     O       O
  395          Serine     phosphorylation     O       O
  398        Asparagine     deamidation       O       O
  403          Serine     phosphorylation     O        
  404          Serine     phosphorylation     O       O
  405        Methionine      oxidation        O       O
  407          Serine     phosphorylation             O
  409          Serine     phosphorylation             O
